Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a ...

A spokesperson said: “Results from the STEP trials demonstrate that weight regain is likely once medication is stopped.

Novo Nordisk A/S (NYSE:NVO) is one of the Best Extremely Profitable Stocks to Buy Right Now. On July 18, Novo Nordisk A/S ...

Goldman Sachs GQG Partners International Opportunities GSIMX has the elements in place to continue to outperform, though the road could be bumpy at times.

Aging America may revive healthcare stocks after a rough year — discover why long-term trends point to a powerful rebound.

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

Founded in 1998, Genmab develops customised antibodies for use in cancer treatments. Historically, the group has licensed its technology and the commercialisation of its drugs to large pharma giants ...

Two months after laying off 20% of its staff, Korro Bio says it has not retreated from its “3-2-1” corporate strategy as it prepares to release interim clinical data on its lead candidate KRRO-110 in ...

I want you to know I don’t want Novo Nordisk… and the reason that is because if there’s going to be talk about tariffs on ...

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of U.S. rate cuts ...